ProfileGDS5678 / 1427416_x_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 43% 45% 54% 45% 45% 41% 42% 44% 45% 52% 44% 45% 44% 44% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.0389743
GSM967853U87-EV human glioblastoma xenograft - Control 23.0345745
GSM967854U87-EV human glioblastoma xenograft - Control 33.34454
GSM967855U87-EV human glioblastoma xenograft - Control 43.0068645
GSM967856U87-EV human glioblastoma xenograft - Control 52.9878145
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.0253541
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.0241942
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.0168944
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.0253545
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.2451552
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.0100544
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.0186145
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.0309844
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.0302144